Cefuroxime Axetil is an orally active prodrug of Cefuroxime. After oral administration, Cefuroxime Axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to release Cefuroxime into the blood stream. Conversion to Cefuroxime, the microbiologically active form, occurs rapidly. The inherent properties of Cefuroxime are unaltered after its administration as Cefuroxime Axetil. Cefuroxime exerts its bactericidal effect by binding to an enzyme or enzymes referred to as penicillin-binding proteins (PBPs) involved in bacterial cell wall synthesis.
Axibid 500 mg tablet: Each tablet contains Cefuroxime Axetil USP equivalent to 500 mg Cefuroxime.
Axibid 250 mg tablet: Each tablet contains Cefuroxime Axetil USP equivalent to 250 mg Cefuroxime.
Axibid (Cefuroxime Axetil) is indicated in the treatment of:
• Upper respiratory tract infections: for example, ear, nose and throat infections such as otitis media, sinusitis, tonsillitis and pharyngitis.
• Lower respiratory tract infections: for example, acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia.
• Skin and soft tissue infections: such as furunculosis, pyoderma, and impetigo.
• Genito-urinary tract infections: such as pyelonephritis, urethritis, and cystitis.
• Gonorrhoea: acute uncomplicated gonococcal urethritis, and cervicitis.
• Early Lyme disease & subsequent prevention of late Lyme disease.
Generally Cefuroxime is well tolerated. However, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. As with other broad-spectrum antibiotics, prolonged administration of Cefuroxime may result in overgrowth of nonsusceptible microorganisms. Rarely (<0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear.
Axibid 500 mg tablet: Each box contains 1 x 7 tablets in Alu-Alu blister strip.
Axibid (Cefuroxime axetil) is a well-characterized and effective antibacterial agent, which has broad-spectrum bactericidal activity against a wide range of common pathogens, including beta-lactamase-producing strains. It is very effective for various types of infections such as-
Gonorrhea: acute uncomplicated gonococcal urethritis, and cervicitis
Axibid (Cefuroxime Axetil) is contraindicated in-patients with known allergy to cephalosporins.
Prolonged use of Cefuroxime axetil may result in the over growth of non-susceptible organisms (e. g. Candida, Enterococci, Clostridium difficile), which may require interruption of treatment
Most infections will respond to 250 mg b. d. In mild to moderate lower respiratory tract infections, e.g. bronchitis, 250 mg b. d. should be given. For more severe lower respiratory tract infections, or if pneumonia is suspected then 500 mg b.d. should be given. For urinary tract infections a dose of 125 mg b. d. is usually adequate; in pyelonephritis the recommended dose is 250 mg b. d. A single dose of one gram is recommended for the treatment of uncomplicated gonorrhoea. Lyme disease in adults and children over the age of 12 years: the recommended dose is 500 mg b .d. for 20 days.
There is no experience in children under three months of age.
The usual course of therapy is seven days.
Cefuroxime should be taken after food for optimum absorption.
Take your missed dose as soon as you remember or, if it is nearly time for your next dose, skip your missed dose altogether
Do not stop taking this medicine without talking to your doctor. You should not stop taking (Axibid) just because you feel better. Patient has to complete full dosage. This is because the problem may come back or get worse again.
Cefuroxime axetil has been associated with nausea and vomiting in a small number of patients
Store in a cool (below 30°C), dry place & protect from light. Keep out of the reach of children
Mascot Plaza, 8th Floor
107/A, Sonargaon Janapath, Sector – 7, Uttara C.A
Dhaka – 1230, Bangladesh.
Phone: (+8802) 58952811, Fax: (+8802) 58955797
48, Tongi Industrial Area
Block-C, Tongi, Gazipur.
Phone: (+8802) 980 2387, Fax: (+8802) 980 2387